Satish Rojekar, Ph.D., M.Pharm, is at the forefront of innovative drug delivery research, focusing on enhancing treatment efficacy, safety, and quality for chronic diseases like obesity, osteoporosis, Alzheimer’s disease, and HIV. His multifaceted work integrates biotherapeutics, nanomedicine, microneedle drug delivery, and pharmaceutical technology to address critical therapeutic challenges and improve patient compliance. A significant aspect of Dr. Rojekar’s research is developing and optimizing monoclonal antibody (mAb) formulations for obesity, osteoporosis, and Alzheimer’s disease, paving the way for effective IND-enabling studies. His expertise extends to lipid nanoparticles (LNPs) for gene delivery, providing targeted and efficient nucleic acid therapies. Additionally, he is working on lyophilized monoclonal antibody formulations and lipid nanocarriers for obesity management, ensuring stable and efficient biologic drug delivery. During PhD, Dr. Rojekar revolutionized nanostructured lipid carriers (NLCs) for HIV reservoir targeting, enhancing drug delivery to infected tissues. His innovative NLC-based combination therapies, such as encapsulating etravirine and selenium nanoparticles, demonstrate synergistic HIV inhibition and oxidative stress reduction. Additionally, his work on plasma-processed formulations enhances solubility and enables extended-release capabilities for better therapeutic outcomes. Beyond his research, Dr. Rojekar leads translational projects and oversees CMC and preclinical development of small and large molecules. He also serves as the Director of the Drug Development and Nanomedicine Core at the Center for Translational Medicine. Actively engaged in peer review, he is an editor for several prestigious journals. Dr. Rojekar holds multiple patents and has numerous high-impact publications. Additionally, he is a member of esteemed organizations, including the AAPS, CRS, Endocrine Society, British Society for Nanomedicine, and ASBMR. Committed to advancing drug delivery technologies and improving therapeutic outcomes, he actively seeks industry collaborations to drive innovation and translational impact.